iosBio
iosBio is a biotechnology company developing innovative oral, thermostable vaccines using proprietary platforms including OraPro™, Enhanced Surface Display (ESD™), and AI-driven antigen design. Their lead candidate, OraPro-EBV, targets Epstein-Barr Virus, addressing a significant unmet medical need linked to diseases such as multiple sclerosis and cancers. The company focuses on needle-free, thermostable vaccines that eliminate cold-chain logistics and enhance global accessibility by generating mucosal and systemic immunity through self-administered capsules. iosBio is advancing OraPro-EBV into Phase 1 clinical trials and aims to transform global vaccination with faster, cost-effective deployment and significant commercial potential.
iosBio
iosBio is a biotechnology company developing innovative oral, thermostable vaccines using proprietary platforms including OraPro™, Enhanced Surface Display (ESD™), and AI-driven antigen design. Their lead candidate, OraPro-EBV, targets Epstein-Barr Virus, addressing a significant unmet medical need linked to diseases such as multiple sclerosis and cancers. The company focuses on needle-free, thermostable vaccines that eliminate cold-chain logistics and enhance global accessibility by generating mucosal and systemic immunity through self-administered capsules. iosBio is advancing OraPro-EBV into Phase 1 clinical trials and aims to transform global vaccination with faster, cost-effective deployment and significant commercial potential.